Follicular occlusion triad: an isotopic response or adverse effect of rituximab?
Identifieur interne : 000379 ( 2020/Analysis ); précédent : 000378; suivant : 000380Follicular occlusion triad: an isotopic response or adverse effect of rituximab?
Auteurs : Jeremiah Au ; Frederick T. Gibson [États-Unis] ; Iris K. AronsonSource :
- Dermatology online journal [ 1087-2108 ] ; 2020.
Abstract
Follicular occlusion triad is a symptom complex of three conditions with a similar pathophysiology including hidradenitis suppurativa (HS), dissecting cellulitis of the scalp, and acne conglobata. Although the exact pathogenesis of the triad is unknown, it appears to be related to follicular occlusion in areas with apocrine glands. Wolf isotopic response refers to the occurrence of a new dermatosis at the site of another, unrelated, previously healed dermatosis. We present a 26-year-old man with a history of pemphigus foliaceus (PF) who developed large draining nodules with scarring and sinus tracts, compatible with follicular occlusion triad, preferentially at areas previously affected by PF thirteen months after treatment with rituximab. To the authors' knowledge there are no reported cases of follicular occlusion triad or HS manifesting as an isotopic response. However, one member of the triad, HS, has been reported to occur infrequently following the use of biologic agents such as adalimumab, infliximab, tocilizumab, and rituximab for chronic immune-mediated inflammatory diseases (psoriasis, Crohn disease, rheumatoid arthritis, and ankylosing spondylitis).
PubMed: 32239887
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000090
- to stream PubMed, to step Curation: 000090
- to stream PubMed, to step Checkpoint: 000152
- to stream Ncbi, to step Merge: 002A73
- to stream Ncbi, to step Curation: 002A73
- to stream Ncbi, to step Checkpoint: 002A73
- to stream Main, to step Merge: 000379
- to stream Main, to step Curation: 000379
- to stream Main, to step Exploration: 000379
- to stream 2020, to step Extraction: 000379
Links to Exploration step
pubmed:32239887Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Follicular occlusion triad: an isotopic response or adverse effect of rituximab?</title><author><name sortKey="Au, Jeremiah" sort="Au, Jeremiah" uniqKey="Au J" first="Jeremiah" last="Au">Jeremiah Au</name></author><author><name sortKey="Gibson, Frederick T" sort="Gibson, Frederick T" uniqKey="Gibson F" first="Frederick T" last="Gibson">Frederick T. Gibson</name><affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, University of Illinois at Chicago, Chicago, IL. fredtg11@gmail.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Illinois</region></placeName><wicri:cityArea>Department of Dermatology, University of Illinois at Chicago, Chicago</wicri:cityArea></affiliation></author><author><name sortKey="Aronson, Iris K" sort="Aronson, Iris K" uniqKey="Aronson I" first="Iris K" last="Aronson">Iris K. Aronson</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32239887</idno><idno type="pmid">32239887</idno><idno type="wicri:Area/PubMed/Corpus">000090</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000090</idno><idno type="wicri:Area/PubMed/Curation">000090</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000090</idno><idno type="wicri:Area/PubMed/Checkpoint">000152</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000152</idno><idno type="wicri:Area/Ncbi/Merge">002A73</idno><idno type="wicri:Area/Ncbi/Curation">002A73</idno><idno type="wicri:Area/Ncbi/Checkpoint">002A73</idno><idno type="wicri:Area/Main/Merge">000379</idno><idno type="wicri:Area/Main/Curation">000379</idno><idno type="wicri:Area/Main/Exploration">000379</idno><idno type="wicri:Area/2020/Extraction">000379</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Follicular occlusion triad: an isotopic response or adverse effect of rituximab?</title><author><name sortKey="Au, Jeremiah" sort="Au, Jeremiah" uniqKey="Au J" first="Jeremiah" last="Au">Jeremiah Au</name></author><author><name sortKey="Gibson, Frederick T" sort="Gibson, Frederick T" uniqKey="Gibson F" first="Frederick T" last="Gibson">Frederick T. Gibson</name><affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, University of Illinois at Chicago, Chicago, IL. fredtg11@gmail.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Illinois</region></placeName><wicri:cityArea>Department of Dermatology, University of Illinois at Chicago, Chicago</wicri:cityArea></affiliation></author><author><name sortKey="Aronson, Iris K" sort="Aronson, Iris K" uniqKey="Aronson I" first="Iris K" last="Aronson">Iris K. Aronson</name></author></analytic><series><title level="j">Dermatology online journal</title><idno type="eISSN">1087-2108</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Follicular occlusion triad is a symptom complex of three conditions with a similar pathophysiology including hidradenitis suppurativa (HS), dissecting cellulitis of the scalp, and acne conglobata. Although the exact pathogenesis of the triad is unknown, it appears to be related to follicular occlusion in areas with apocrine glands. Wolf isotopic response refers to the occurrence of a new dermatosis at the site of another, unrelated, previously healed dermatosis. We present a 26-year-old man with a history of pemphigus foliaceus (PF) who developed large draining nodules with scarring and sinus tracts, compatible with follicular occlusion triad, preferentially at areas previously affected by PF thirteen months after treatment with rituximab. To the authors' knowledge there are no reported cases of follicular occlusion triad or HS manifesting as an isotopic response. However, one member of the triad, HS, has been reported to occur infrequently following the use of biologic agents such as adalimumab, infliximab, tocilizumab, and rituximab for chronic immune-mediated inflammatory diseases (psoriasis, Crohn disease, rheumatoid arthritis, and ankylosing spondylitis).</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Illinois</li></region></list><tree><noCountry><name sortKey="Aronson, Iris K" sort="Aronson, Iris K" uniqKey="Aronson I" first="Iris K" last="Aronson">Iris K. Aronson</name><name sortKey="Au, Jeremiah" sort="Au, Jeremiah" uniqKey="Au J" first="Jeremiah" last="Au">Jeremiah Au</name></noCountry><country name="États-Unis"><region name="Illinois"><name sortKey="Gibson, Frederick T" sort="Gibson, Frederick T" uniqKey="Gibson F" first="Frederick T" last="Gibson">Frederick T. Gibson</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000379 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000379 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= 2020
|étape= Analysis
|type= RBID
|clé= pubmed:32239887
|texte= Follicular occlusion triad: an isotopic response or adverse effect of rituximab?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/RBID.i -Sk "pubmed:32239887" \
| HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |